Trials / Completed
CompletedNCT01460381
A Study to Evaluate the Effect of Genotype on LY2216684
A Study to Investigate the Effect of CYP2C19 Phenotype on the Pharmacokinetics of LY2216684 in Healthy Subjects
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 18 (actual)
- Sponsor
- Eli Lilly and Company · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Accepted
Summary
The study will evaluate how genetic profiles respond to LY2216684 and the effect of Quinidine on the pharmacokinetics (PK) of LY2216684 in a specific genetic profile. Side effects will be documented.
Detailed description
The human cytochrome P450 2C19 (CYP2C19) enzyme is a polymorphic enzyme yielding ultrarapid metabolizer, extensive metabolizer (EM), intermediate metabolizer, and poor metabolizer (PM) phenotypes. Enrollment in the study was limited to participants predicted to be CYP2C19 extensive metabolizers or CYP2C19 poor metabolizers, as determined by genotyping analysis.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | LY2216684 | |
| DRUG | Quinidine |
Timeline
- Start date
- 2011-10-01
- Primary completion
- 2012-08-01
- Completion
- 2012-08-01
- First posted
- 2011-10-26
- Last updated
- 2018-10-26
- Results posted
- 2018-10-26
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT01460381. Inclusion in this directory is not an endorsement.